OCT 07, 2019 11:51 AM PDT

Evolutionary-Busting Cancer Drug

WRITTEN BY: Nouran Amin

Researchers at the Institute of Cancer Research in London have discovered that a new type of drug that blocks treatment in cancers. The drug works by inhibiting a cancer's key evolutionary escape route from chemotherapy which can be used to treat aggressive breast cancer. Known as BOS172722, the drug forces cancer cells to multiply quickly by blocking the activity of a molecule called MPS1.

Learn more about treatment-resistant cancers and previous studies regarding developing therapeutics to combat such a challenge:

"We have discovered a brand new type of cancer treatment that uses cancer's rapid growth against it, by forcing cells through cell division so quickly that they accumulate fatal errors. The drug works especially well in combination with chemotherapy in triple negative breast cancer cells -- the deadliest form of breast cancer for which there are few successful treatments,” says Professor Spiros Linardopoulos, Professor of Cancer Biology and Therapeutics at The Institute of Cancer Research, London.

"Crucially, the combination is anticipated to be effective in cancer patients that have already become resistant to chemotherapy alone and has the potential to become a much-needed extra treatment option that could extend the lives of patients. The phase I trial of this combination is currently well under way and I look forward to the results."

The evolution-busting therapeutic will begin its first clinical trial on solid tumors such as aggressive triple-negative breast cancers and may also be effective against ovarian cancer. Findings of the study published in the journal Molecular Cancer Therapeutics explains the sensitivity of some cancers upon blocking MPS1 even at low doses.

"Cancer's ability to evolve and become drug resistant is the cause of the vast majority of deaths from the disease. We plan to counter that ability with the world's first 'Darwinian' drug discovery programme within our Centre for Cancer Drug Discovery, dedicated to creating a new generation of anti-evolution treatments,” says Professor Rajesh Chopra, Director of Cancer Therapeutics in the new Centre for Cancer Drug Discovery.

Source: Science Daily

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 17, 2019
Drug Discovery & Development
OCT 17, 2019
How Does Ecstasy Treat PTSD?
Conventionally, Post Traumatic Stress Disorder (PTSD) is treated via talk therapy, with the aim of getting patients to open up about their trauma and rewir...
OCT 17, 2019
Drug Discovery & Development
OCT 17, 2019
Comparison of Three Frontline Breast Cancer Drugs
Breast cancer affects 250,000 women in the U.S. annually. Those with most common form test positive for hormone receptors (HR+) and negative for the HER2 r...
OCT 17, 2019
Drug Discovery & Development
OCT 17, 2019
Adderall is Almost Identical to Crystal Meth
Adderall has a reputation for giving people a feeling of euphoria, increasing energy levels and enhancing abilities to focus and concentrate. And coinciden...
OCT 17, 2019
Drug Discovery & Development
OCT 17, 2019
Peptide-Based Therapeutics Advances Alzheimer Disease Research
Affecting 44 million individuals globally, Alzheimer’s disease (AD) is a form of dementia characterized by loss of brain cells, inflammation and vasc...
OCT 17, 2019
Microbiology
OCT 17, 2019
The Antimicrobial Power of Mucus is Revealed
We produce several liters of mucus every day to cover more than 200 square meters in the human body....
OCT 17, 2019
Drug Discovery & Development
OCT 17, 2019
Common Drug May Prevent Thousands Deaths from Head Injury
Each year, there are over 60 million new cases of traumatic brain injury (TBI). Mostly caused by road traffic crashes and falls, TBI often causes intracran...
Loading Comments...